Debiopharm International SA Awarded $2.6 Million Grant from CARB-X to Support Development of Debio 1453 to fight drug resistant gonorrhea
Lausanne (ots) - Debiopharm, in collaboration with CARB-X, will utilize their state-of-the-art Fabiotics platform to develop novel therapeutics to combat drug-resistant gonorrhea. Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical ...
Zurich (ots) - Sequana Medical AG ("Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, announces the publication of a multicentre, randomized controlled trial in the Journal of Hepatology (http://ots.ch/w2er5). The study demonstrated that in patients with refractory ascites,
the alfapump®: - significantly reduces the requirement for LVP compared to standard of care - significantly improves Health-Related Quality of Life compared to standard of care - shows nutritional benefits compared to standard of care This multicentre, randomized controlled trial assessed safety and efficacy of the alfapump® (AP) ...
ImmunoQure AG announces publication in Cell of naturally occurring patient-derived autoantibodies that limit human diseases
Düsseldorf (ots) - ImmunoQure AG, a German biotechnology company focused on the development of autoantibodies as therapeutics to treat common human diseases today announced the publication of data in the leading scientific journal Cell, demonstrating that such therapeutics can limit a variety of common human ...
First preclinical proof-of-concept of mutation-based individualized cancer vaccine / Deep sequencing of immunogenic mutations may pave way for customized immunotherapy
Mainz (ots) - The Institute of Translational Oncology (TRON) together with BioNTech AG today announced the publication of a joint paper in the international journal Cancer Research that describes a new path for individually tailored cancer therapy. An interdisciplinary team of genome scientists and immunologists led ...
Hilden, Germany, and Gaithersburg, Md. (ots) - Vaginal self-collection for Hybrid Capture®-based HPV testing increases screening coverage and is more sensitive than Pap smear shows a Mexican study published today online in the Lancet Promising findings published today online in the Lancet[i] from a community- ...
ERA-EDTA congress 2011: Late Breaking Clinical Trials I / RAVE study: In ANCA-associated vasculitis rituximab is just as effective and safe as standard therapy
Prague, Czech Republic (ots) - The randomised, double-blind, placebo-controlled multi-centre study (abstract no. 2511) investigated the efficacy and safety of the monoclonal antibody rituximab (RTX) in 197 ANCA-associated vasculitis (AAV) patients. This study showed that in patients with severe AAV a single course ...
Prag (ots) - The congress of the ERA-EDTA (European Renal Association and European Dialysis and Transplant Association) is the biggest congress in Europe on nephrology and renal replacement therapy. You are cordially invited to attend this Congress. The Opening Press Conference will be held on Thursday 23rd June, 11 am (Corinthia Hotel). Topic: Can the high ...
- Migros - Genossenschafts - Bund
- 3D Systems
- SRG SSR
- Egmont Ehapa Media GmbH
- Kapsch TrafficCom AG
- RTL II
- Kreisel Electric GmbH
- Janssen Pharmaceutica
- Peach Property Group AG
- Caritas Schweiz / Caritas Suisse
- SDBB / CSFO
- Ministry of Foreign Affairs, Thailand
- McKinsey & Company
- Touring Club Schweiz/Suisse/Svizzero - TCS
- Edstrom Industries LLC
- Volvo Cars Group
- TOYS "R" US GmbH
- Eldorado Gold Corporation